In contrast, ICC 2022 excludes cases without SF3B1 mutation in this category as SF3B1-unmutated MDS-RS cases have clinical features and outcomes similar to MDS with SLD or MLD and are now classified as MDS, NOS, irrespective of the number of RS. Here, SF3B1 is linked to myelodysplastic syndrome.